Beone Medicines Ltd. Class A — Fact Sheet (May 2025)

2 slides from Beone Medicines Ltd. Class A's fact sheet, May 2025

Slide 1: BeOne Medicines Corporate Overview
BeOne Medicines Corporate Overview BeOne is a global oncology company driven by Our integrated model has delivered innovative, internally discovered medicines that are transforming standards of care scientific excellence and exceptional speed to worldwide: BTK inhibitor BRUKINSA® (zanubrutinib) and
Slide 2: Facts at a Glance
Facts at a Glance ~12k $3.8B ~2M 40+ Colleagues globally 2024 total revenue* Patients treated Assets in clinical in over 4 0 offices with our and commercial on 6 continents medicines stages 1.2k+ 3.8k+ In-house manufacturing 40+ Oncology global clinical including diversified Phase 3 or potentially r